Dr. Christi Kim is an assistant professor in clinical medicine and a general medical oncologist with special interest in gynecologic cancer and lymphoma. She is a member of Yale Cancer Center Developmental Therapeutics and NRG Publication Committee. She is Yale Institutional Review Board member. She has participated in Gynecologic Oncology Group (GOG) clinical trial as a primary investigator - GOG-3059, phase 3 placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer. As a member of Society of Gynecologic Oncology (SGO) Clinical Practice Committee, she co-authored "Neuroendocrine Tumors of the Gynecologic Tract Update", published in Gynecologic Oncology, the official publication of the SGO. She is an active member of International Gynecologic Cancer Society (IGCS). She was appointed as adjunct assistant professor at Icahn School of Medicine at Mount Sinai. She is committed to improve the lives of those who are impacted by cancer. She feels passionate about providing the best evidence-based therapy options personalized to each patient. She is committed to advancing the field of oncology through clinical trial. She is fluent in Korean.